Recommendation of the President – Keytruda (pembrolizumab)
On 21 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 8/2026 on the reimbursement of the medicinal product Keytruda (pembrolizumab) under the B.58 drug program “Treatment of patients with esophageal and gastroesophageal junction cancer (ICD-10: C15-C16)”